Previous 10 | Next 10 |
HOUSTON, May 05, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced that the Company will host a conferenc...
HOUSTON, April 29, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today the titles of the abstracts acce...
HOUSTON, April 19, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc . (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that all three submitted abstra...
SLRX is a low market cap early-stage cancer therapeutics company. It has a very low cash reserve. Its science looks interesting. For further details see: Salarius: Early Stage Nano Cap Targeting Cancer
Hot Penny Stocks to Watch If Biotech is Your Focus Investors continue looking for the best penny stocks to buy. With the way the stock market has been lately, that’s easier said than done. But the potential that these cheap shares bring is unlike anything else out there. ...
Wah Fu Education Group (WAFU) +82%.180 Life Sciences (ATNF) +49%.NextDecade Corporation (NEXT) +31% on signing term sheet with Occidental Petroleum.Four Seasons Education (Cayman) (FEDU) +26%.Banco Santander Mexico SA ADR (BSMX) +19%.China Liberal Education Holdings Limited (CLEU) +18%.L...
Salarius Pharmaceuticals, Inc. (SLRX) Q4 2020 Earnings Conference Call March 18, 2021, 16:30 ET Company Participants Jason Rando - Tiberend Strategic Advisors David Arthur - CEO, President & Director Mark Rosenblum - EVP, Finance & CFO Nadeem Mirza - SVP, Clinical Development Daniela ...
Salarius Pharmaceuticals (SLRX): Q4 GAAP EPS of -$0.10 beats by $0.01.Revenue of $1.48M (+42.3% Y/Y) in-line.“In terms of our financial and cash position, Salarius has never been on stronger footing. The $23 million public offering we closed last week, in addition to other recent finan...
HOUSTON, March 18, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today reported important corporate events and its fi...
HOUSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced that the Company will host a con...
News, Short Squeeze, Breakout and More Instantly...
Salarius Pharmaceuticals Inc. Company Name:
SLRX Stock Symbol:
NASDAQ Market:
Salarius Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 1.7% to $112.28 on volume of 455,296,152 shares Ford Motor Company (F) fell 18.4% to $11.16 on volume of 256,384,806 shares PROSHARES TRUST (SQQQ) rose 3.4% to $9.37 on volume of 246,885,889 shares Sel...
Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) is one of today's top gainers. The company's shares have moved 57.21% on the day to $3.37. Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Secli...
A look at the top 10 most actives in the United States Predictive Oncology Inc. (POAI) rose 115.9% to $2.3099 on volume of 63,737,015 shares Selina Hospitality PLC (SLNA) fell 11.2% to $0.0406 on volume of 59,708,638 shares NVIDIA Corporation (NVDA) fell 1.4% to $112.695 on volume of 52,2...